DK3496743T3 - Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler - Google Patents

Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler Download PDF

Info

Publication number
DK3496743T3
DK3496743T3 DK17840420.8T DK17840420T DK3496743T3 DK 3496743 T3 DK3496743 T3 DK 3496743T3 DK 17840420 T DK17840420 T DK 17840420T DK 3496743 T3 DK3496743 T3 DK 3496743T3
Authority
DK
Denmark
Prior art keywords
immunooncological
agents
compositions
methods
treating cancer
Prior art date
Application number
DK17840420.8T
Other languages
English (en)
Inventor
David Lowe
Scott W Rowlinson
Susan Alters
Giulia Agnello
Original Assignee
Aerase Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerase Inc filed Critical Aerase Inc
Application granted granted Critical
Publication of DK3496743T3 publication Critical patent/DK3496743T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK17840420.8T 2016-08-08 2017-09-08 Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler DK3496743T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662372092P 2016-08-08 2016-08-08
US201762524286P 2017-06-23 2017-06-23
PCT/US2017/050816 WO2018032020A1 (en) 2016-08-08 2017-09-08 Compositions and methods for treating cancer with arginine depletion and immuno oncology agents

Publications (1)

Publication Number Publication Date
DK3496743T3 true DK3496743T3 (da) 2022-04-04

Family

ID=61163268

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17840420.8T DK3496743T3 (da) 2016-08-08 2017-09-08 Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler

Country Status (19)

Country Link
US (2) US10729752B2 (da)
EP (1) EP3496743B1 (da)
AU (1) AU2017310541B2 (da)
BR (1) BR112019002458A2 (da)
CY (1) CY1125158T1 (da)
DK (1) DK3496743T3 (da)
ES (1) ES2909556T3 (da)
GB (1) GB2568000A (da)
HR (1) HRP20220406T1 (da)
HU (1) HUE057901T2 (da)
IL (1) IL264535B (da)
LT (1) LT3496743T (da)
PL (1) PL3496743T3 (da)
PT (1) PT3496743T (da)
RS (1) RS63075B1 (da)
RU (1) RU2771313C2 (da)
SI (1) SI3496743T1 (da)
SM (1) SMT202200157T1 (da)
WO (1) WO2018032020A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2568000A (en) 2016-08-08 2019-05-01 Aerase Inc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
US12508306B2 (en) 2018-04-25 2025-12-30 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
WO2020063668A1 (zh) * 2018-09-25 2020-04-02 信达生物制药(苏州)有限公司 包含抗ox40抗体的制剂、其制备方法及其用途
WO2020081994A1 (en) 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
KR20220082813A (ko) * 2019-08-30 2022-06-17 아이글레아 바이오테라퓨틱스, 인크. 인간 재조합 아르기나아제 1의 제조 방법 및 이의 사용
WO2022195629A1 (en) * 2021-03-18 2022-09-22 National Institute Of Pharmaceutical Education And Research (Niper) Engineered arginase constructs, method of generation and uses thereof
CN118497178A (zh) * 2023-02-15 2024-08-16 重庆派金生物科技有限公司 精氨酸脱亚胺酶突变体、共价二聚体及其偶联物和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02117383A (ja) 1988-10-26 1990-05-01 Tosoh Corp ヒトアルギナーゼの製造方法
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
WO2003063780A2 (en) 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio-Cancer Treatment International Limited Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
CN1745847A (zh) 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
CA2742497C (en) 2008-10-31 2024-01-23 George Georgiou Compositions of engineered human arginases and methods for treating cancer
WO2011008495A2 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
WO2012061015A2 (en) * 2010-11-03 2012-05-10 Scott & White Healthcare L-citrulline supplementation during arginine depletion therapy with arginase
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP3690044B1 (en) 2014-02-11 2024-01-10 The Regents of the University of Colorado, a body corporate Crispr enabled multiplexed genome engineering
EP3134546A4 (en) * 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP2982758A1 (en) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
PT3186281T (pt) * 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
CA2966523A1 (en) * 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
US20180271960A1 (en) * 2015-09-21 2018-09-27 Bio-Cancer Treatment International Ltd. Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
GB2568000A (en) 2016-08-08 2019-05-01 Aerase Inc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents

Also Published As

Publication number Publication date
PL3496743T3 (pl) 2022-05-30
EP3496743B1 (en) 2022-02-09
CY1125158T1 (el) 2024-02-16
RU2771313C2 (ru) 2022-04-29
PT3496743T (pt) 2022-03-30
RU2019106501A3 (da) 2021-01-15
RU2019106501A (ru) 2020-09-14
EP3496743A1 (en) 2019-06-19
WO2018032020A1 (en) 2018-02-15
SI3496743T1 (sl) 2022-08-31
HRP20220406T1 (hr) 2022-05-27
LT3496743T (lt) 2022-04-11
US20180177853A1 (en) 2018-06-28
BR112019002458A2 (pt) 2019-05-14
IL264535A (en) 2019-02-28
SMT202200157T1 (it) 2022-05-12
GB201903065D0 (en) 2019-04-24
US10729752B2 (en) 2020-08-04
IL264535B (en) 2022-01-01
RS63075B1 (sr) 2022-04-29
ES2909556T3 (es) 2022-05-09
AU2017310541A1 (en) 2019-03-07
EP3496743A4 (en) 2020-03-18
GB2568000A (en) 2019-05-01
US20200360493A1 (en) 2020-11-19
HUE057901T2 (hu) 2022-06-28
AU2017310541B2 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
DK3496743T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler
DK3245225T3 (da) Sammensætninger og fremgangsmåder til behandling og detektering af cancere
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3303317T3 (da) Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner
IL258688A (en) Compositions and methods for viral cancer neoepitopes
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3386518T3 (da) Metoder og sammensætninger til behandling af en serpinc1-associeret forstyrrelse
DK2994533T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3206497T3 (da) Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3377516T3 (da) Sammensætning til behandling af cancer
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3624837T3 (da) Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
DK2941258T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3102232T3 (da) Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3380086T3 (da) Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3478284T3 (da) Forbindelser og sammensætninger til behandling af cancer